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ABSTRACT
Lung cancer remains the leading cause of cancer death
globally, yet with many recent advances in the diagnosis
and treatment of lung cancer, the face of the disease is
shifting. Historically, lung cancer is often thought of as a
predominantly male disease with more than twice as many
men as women being diagnosed worldwide—mostly due to
the influence of smoking as the leading risk factor. How-
ever, lung cancer is also the second leading cause of cancer
death in women and there is a growing population of
young women who have never smoked and are being diag-
nosed. The past decade has seen groundbreaking innova-
tions in both the early detection and treatment of lung
cancer. In this new era, survival rates are beginning to
increase and many of those diagnosed are finding them-
selves in a new situation—living long term with a deadly
cancer. Here, we review pertinent aspects of women and
lung cancer as well as the concept of living with lung can-
cer as a chronic disease to give a new perspective on the
changing face of lung cancer treatment and care.
Key words: chronic disease, gender differences, lung cancer,
survivorship.
INTRODUCTION
Due to changes in worldwide smoking patterns from pre-
vention efforts, the advent of lung cancer screening, and
significant advancements in lung cancer treatment
options, the population of people living with lung cancer
today is shifting. Within this population, there are over-
lapping subgroups characterized by two key dichotomies:
women living with a predominantly male disease and
people living long term with a deadly cancer.
Lung cancer is the third most frequently diagnosed
cancer and the second leading cause of cancer-related
death among women. As in men, the main risk factor
for women is cigarette smoking. However, the higher
percentage of this disease in younger and non-smoking
women, as compared with younger and non-smoking
men, suggests the presence of other biological factors
which render female lung cancers a distinctive entity,
with implications for epidemiology, prevention and
treatment. Hormonal status is a potential explanation:
oestrogens are involved in lung cancer development
and evolution through cell proliferation induced by
oestrogen receptor (ER) interaction and cross-talk
between ER and growth factor receptors. Furthermore,
immunotherapeutic approaches in current clinical
practice suggest that gender differences in the immune
system influence dissimilar evolution of solid tumours.
Improved diagnosis and treatment now mean that
patients with lung cancer are living longer than ever
before. Around the globe, more and more people are
balancing the great hope and vast uncertainty of living
with advanced lung cancer as a chronic disease. A
chronic disease lasts 1 or more years, requires ongoing
medical attention and/or limits activities of daily living.
If uncontrolled, any chronic disease can be life threat-
ening. Little is known about how to live long term with
a disease that has traditionally been lethal. This group
faces a unique dichotomy of embracing survivorship
while still living with a deadly disease. New manage-
ment strategies and interventions are needed to ensure
both proper medical care and appropriate psychosocial
support for this growing population.
This review summarizes the literature and evidence
for these two overlapping groups of people with lung
cancer as well as the many questions that remain to
ensure the best treatment and survivorship care.
THE DICHOTOMY OF LUNG CANCER
IN WOMEN
Introduction
Literature suggests that lung cancer development and
evolution is different between men and women.
Correspondence: Maria Lucia Reale, Department of Oncology,
AOU San Luigi Regione Gonzole, 10, 10043 Orbassano, Torino,
Italy. Email: realemarialucia@gmail.com; Jennifer C. King, GO2
Foundation for Lung Cancer, 1700 K Street, NW, Suite
660, Washington DC 20006, USA. Email: jking@go2foundation.org
*T.V. and M.R. contributed equally to this study.
‡S.N. and J.C.K. are equal senior contributors.
Received 10 February 2020; invited to revise 4 July 2020;
revised 16 July 2020; accepted 13 October 2020
© 2020 Asian Pacific Society of Respirology Respirology (2020)
doi: 10.1111/resp.13965
Considering a dissimilar biology and clinical presentation,
lung cancer in women should be judged as a distinctive
entity.1,2 About 20% of women (vs 7% of men) with a lung
cancer diagnosis have never smoked; as a consequence,
hormonal influences are under investigation.3,4 In the last
few years, immunotherapeutic approaches highlighted
gender differences in the immune system as possibly
influencing a different evolution of solid tumours and
lung cancer.5,6
However, despite these scientific progresses, no
‘gender-driven’ approaches are presently available.
Personalized sex-based investigations need to be fully
developed to significantly improve knowledge about
lung cancer in women.
Epidemiology
Lung cancer is the most commonly diagnosed cancer
(11.6% of total cases) and the leading cause of cancer
death worldwide (18.4% of total cancer deaths).7 It is
the most common cancer among men, with the highest
rates in Eastern Asia and Eastern Europe, but consider-
ably lower rates in Africa (Fig. 1).7
Among women, it is the third most frequently diag-
nosed cancer after breast and colorectal cancer. It rep-
resents 8.4% of all female cancers, with more than
720 000 new lung cancer cases in 2018. Rates are
highest in North America, Northern and Western
Europe and Australia/New Zealand. Incidence varies
among regions according to different smoking habits,
type of exposures, quantity and duration of tobacco
consumption (Fig. 1).7
Lung cancer is the leading cause of cancer death in
men in most countries and the second leading cause of
cancer death among women, representing 13.8% of all
cancer cases, with more than 570 000 deaths in 2018.8
Smoking trends and lung cancer risk
Overall, 71% of all lung cancer deaths and about half of
female lung cancer deaths are linked to tobacco con-
sumption.9 Similar to men, women with a smoking
history have a 25-fold increased risk of death from lung
cancer compared to never-smokers. For those who quit
smoking, the risk gradually decreases over the next
10–15 years.10–12
The controversial theory that females can be more
vulnerable to the negative consequences of tobacco
use has been analysed in prospective studies, which
did not confirm a higher risk of lung cancer among
females than males with similar levels of tobacco
use.13,14
Lung cancer also occurs among never-smokers. This
subgroup presents with specific clinical and demo-
graphic characteristics: adenocarcinoma as the most
prevalent histology, higher socio-economic status,
fewer comorbidities, Hispanic or Asian ethnicity and
oncogenic addiction. It is significant that two-third
cases of lung cancer in never-smokers occur in women,
and that epidermal growth factor receptor (EGFR)
mutation is more common in never-smokers than in
previous or current smokers (51% vs 10%) and in
women rather than in men (42% vs 14%; all
P < 0.001).15,16,17
Environmental tobacco smoke and additional
risk factors
Second-hand smoke also causes lung cancer. The
highest mortality rate in this context occurs among
women, particularly in societies with high rates of male
smoking but low rates of female smoking.18 In the
United States, an estimated 3000 never-smoking
women die each year from lung cancer because of
second-hand smoke.19 The prevalence of second-hand
smoke exposure for females is approximately 60%
higher than for men. Differences among countries are
substantial and depend on smoking habits, workplace
exposure (in regions where no robust smoke-free poli-
cies exist) and home exposure, where women are par-
ticularly affected by restricted indoor spaces, fumes
from cooking or heating systems and inadequate venti-
lation systems.18 Indoor fumes, such as from cooking
oil, are important risk factors in several countries. The
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Figure 1 Incidence of lung cancer
by country among men ( ) and
women ( ) in 2018. The numbers
on the bars indicate the new cases
in each country. Data extrapolated
and elaborated from GLOBOCAN
2018.7
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similar incidence of lung cancer among Chinese and
Western European women, despite considerable diver-
gence in tobacco consumption between the two
regions, may be related to high exposure to kitchen
and carbon particles.7,20
Environmental or occupational substances such as
asbestos, radon, chromium, arsenic, beryllium, vinyl
chloride and polycyclic aromatic hydrocarbons are rec-
ognized as lung carcinogens.21 These exposures have
been analysed in patients with lung cancer that have
known oncogenic driver mutations, a population that is
predominantly female. Radon exposure is the leading
risk factor for lung cancer among never-smokers. Dif-
ferent studies evaluated correlations between radon
exposure and genetic alterations typically expressed by
never-smokers, such as EGFR mutations or anaplastic
lymphoma kinase (ALK) translocations; however,
results were not conclusive.22,23 A multicentre Spanish
case–control study compared median values of residen-
tial radon between never-smoker patients (80% of
whom were female) with EGFR mutations or ALK
translocations with those without a recognized onco-
gene addiction, obtaining statistically insignificant dif-
ferences.22 Another prospective study analysed indoor
radon concentrations in EGFR or BRAF mutated and
ALK rearranged lung cancer patients (69% of whom
were female) detecting a median concentration above
World Health Organization (WHO) recommendations
in more than 50% of patients, with no differences
among the three molecular subgroups.24
Some studies have suggested that pre-existing lung
diseases increase the risk of lung cancer in women.25
A recent meta-analysis confirmed the potential con-
nection between emphysema, chronic bronchitis,
pneumonia, tuberculosis and lung cancer risk, even
after adjustment for smoking status with no differ-
ences between men and women.26 Additional
research, specifically focused on the non-smoking and
female population, is needed to better understand the
potential relationship between these conditions and
lung cancer.
A personal history of previous oncological diseases is
considered another important risk factor for lung can-
cer. A recent study demonstrated that the rate of lung
cancer increased among breast cancer patients who
received radiation therapy compared to breast cancer
patients who did not receive it. The risk is augmented
in active-smoker patients.27
Viral infections can be involved in the development
of lung cancer and gender differences may be involved.
Ragin et al. documented an increased prevalence of
human papillomavirus (HPV) in lung cancer cells than
in non-cancerous cells.28 Bae and Kim showed a signif-
icant effect of HPV infection in lung cancer in never-
smoking women; in particular the summary odds ratio
for lung cancer associated with HPV infection was 5.32
for women and 4.78 for the never-smokers. Further
studies on the potential role of viral infections in lung
cancer are needed.29
Gender-specific data about the effects of physical
exercise or a controlled diet are still poor. For now,
public health strategies recognize the value of healthy
food and physical activity in cancer prevention.30
Lung cancer prevention and early detection
Global reduction in tobacco consumption reflects pro-
gress in many countries to implement tobacco control
measures. According to the WHO global report on
trends in prevalence of tobacco use 2000–2025 third
edition, 136 countries have already established at least
one of the recommended measures of tobacco control
and 116 countries are seeing their tobacco use rates
decline.31,32 Multiple activities and campaigns coordi-
nated by public institutions, scientific societies and
patient associations led to reductions in lung cancer
incidence and mortality. The Centers for Disease Con-
trol and Prevention (CDC), for example, recommends
statewide programmes informing about tobacco risks
with mass-reach health communication interventions
(through television, radio and social media), preventing
initiation, promoting quitting with specific cessation
services, eliminating exposure to second-hand smoke
with specific smoke-free policies that increase tobacco
product prices and decrease tobacco product market
and availability. Furthermore, clinicians are called to
identify and document patients’ tobacco use and to
treat smokers in a healthcare setting (with counselling
and medications, if needed).33
The large, randomized NELSON trial demonstrated
the value of low-dose computed tomography
(CT) screening in significantly reducing lung cancer
mortality in people at high risk of developing lung can-
cer. The cumulative rate ratio for death from lung can-
cer at 10 years was 0.76 in the screening group as
compared with the control group in high-risk men
(main analysis). Subanalyses of data among women
(a small subsample) showed a rate ratio for death from
lung cancer of 0.67 (Table 1).34 These data suggest that
lung cancer screening could be more effective in
women, even if the number of women in the study was
relatively low. Final data, from more extensive analyses,
are still to come.34,35
Hormonal influences
Scientific literature suggests that lung cancer is affected
by gender-specific factors. In particular, oestrogens
play a significant role not only in normal lung tissue
development, but also in lung inflammation and, possi-
bly, lung cancer pathophysiology.36
ER belong to the nuclear steroid receptor superfam-
ily, regulating expression of genes implicated in signal
transduction, cell cycle control and survival. Two differ-
ent genes encode for ER proteins (ERα and ERβ)
expressed in different tissues and with variable distri-
bution (i.e. normal breast tissue expresses both ERα
and ERβ, whereas in lung, ERβ seems to be the domi-
nant form).37–40 Two studies hypothesized a prognostic
value of ERα expression; however, no correlation with
survival or poor prognosis was found, nor were there
clear gender differences.4,39,41 Interactions between ER
and EGFR pathways were recently suggested:
oestrogens induce transcription of oestrogen-
responsive genes in the nucleus of lung cells and trans-
activate the EGFR and other growth factor signalling
pathways.42 While the ERα protein has been detected
in lung tumours harbouring EGFR mutations on exon
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21, it seems that major biological effects are largely
mediated by ERβ which is the key ER expressed in lung
cancer. For now, a possible impact on gender-specific
treatment is still unknown.43–47
With regard to progesterone, Ishibashi et al.
described progesterone-synthesizing enzymes, such as
StAR, P450scc and 3βHSD, in non-small cell lung can-
cer (NSCLC) tissues from 42 patients. This observation
was confirmed in vitro, consequently progesterone
receptor (PR) expression in NSCLC tissue could poten-
tially be associated with local progesterone production
and its subsequent activity.48–50 However, clinical stud-
ies describing a correlation between low PR expression
and prognosis in NSCLC patients are still controversial.
In some pre-clinical studies, progesterone supplemen-
tation seems to inhibit PR-positive lung tumours evolu-
tion while in others, tumour progression was inhibited
by its depletion.49
Further research is required to better understand the
complex interaction between oestrogen and progester-
one and possible hormonal effect on development and
prognosis of lung cancer in women.
Gender perspectives towards
immunotherapy approaches
Qu et al. demonstrated gender differences of the
immune system in a study of primary cultures of
human T cells. This was confirmed by Pinto et al., who
reported differential enrichment of immune-related
genes in women.51,52
Immunological pathways and relevant components
of tumour-induced immunosuppression such as cyto-
toxic T-lymphocyte protein 4 (CTLA-4) and
programmed death-ligand 1 (PD-L1) are under evalua-
tion for their potential impact on gender differences in
lung cancer. Several meta-analyses have been recently
completed on this topic.53–56
Botticelli et al. selected 36 phase II–III clinical trials.
In the cohort of NSCLC patients, they documented no
significant benefit with anti-programmed death-1 (PD-
1) in overall survival (OS) nor in progression-free sur-
vival (PFS) in males versus females (hazard ratio (HR):
0.72, 95% CI: 0.64–0.83 vs HR: 0.81, 95% CI: 0.70–0.94,
P = 0.285, HR: 0.66, 95% CI: 0.52–0.82 vs HR: 0.85, 95%
CI: 0.66–1.09, P = 0.158, respectively).52
Wu et al. suggested in 2018 that males had a longer
OS and PFS than females when treated with immune
checkpoint inhibitors (ICI) versus controls, but that dif-
ference was not significant in NSCLC cohort trials. Of
note, these analyses were biased by heterogeneity of
trials, consideration of different cancer types and
missing data about hormonal and PD-L1 status
according to sex.54
Grassadonia et al. evaluated 12 635 patients with
advanced cancer in 21 randomized controlled trials
(RCT), finding that ICI were associated with more
favourable outcomes in men, particularly considering
anti-CTLA-4 agents.55
In a similar manner, Conforti et al. considered
11 351 patients with advanced cancers in their meta-
analysis (67% men and 33% women). Of the overall
cohort, 3482 (31%) were NSCLC patients, of whom
1478 were women. The pooled OS HR was 0.72 (95%
CI: 0.65–0.79) in men and 0.86 (95% CI: 0.79–0.93) in
women treated with ICI versus (respectively) men and
women in the control groups.5 Despite the large num-
ber of patients analysed, a smaller number of women
was finally considered; in half of the included trials,
women represented less than one-third of the overall
population. The under-representation of women limits
research on the interaction between gender and effi-
cacy of ICI, also considering that previous observations
were from meta-analyses and not from individual stud-
ies, which were underpowered to explore the effect of
gender disparities on outcomes. Lastly, other biological
variables might have influenced final results.56
These considerations were strengthened by Wallis
et al., who evaluated a total of 23 studies in their meta-
analysis. A total of 13 721 patients were included, of
whom 67.9% were men and 32.1% women with advanced
cancer. In particular, 11 selected trials concerned NSCLC
patients while two involved small cell lung cancer (SCLC)
patients, with a total number of 5424 male patients to
2682 females.57 In contrast to Conforti et al., in this meta-
analysis there were no gender differences in OS from
immunotherapy, with a benefit found for both men (HR:
0.75, 95% CI: 0.69–0.81, P < 0.001) and women (HR: 0.77,
95% CI: 0.67–0.88, P = 0.002).57 These contradictory
results may be explained by a different study selection in
terms of type of ICI and regimens (Wallis et al., in con-
trast to Conforti et al., included, for instance,
atezolizumab in their final evaluation), and an update
with seven additional trials.5,57
The meta-analysis of Wang et al. with 9583 advanced
lung cancer patients from 15 RCT (68.5% men and
31.5% women) documented a significant OS and PFS
benefit from both PD-1/PD-L1 inhibitors alone and
PD-1/PD-L1 plus chemotherapy in male patients. In
contrast, in females, the benefit of ICI was less consis-
tent: a PFS advantage was observed in the anti-PD-L1
treatment (HR: 0.56, 95% CI: 0.45–0.69) and combina-
tion therapy (HR: 0.53, 95% CI: 0.43–0.64), while OS
benefit was only found for the anti-PD-1 treatment
Table 1 Lung cancer mortality with volume CT screening (data extrapolated from the NELSON trial)
Lung cancer mortality rate ratio in screening
group compared to control arm (95% CI) 8-Year follow-up 9-Year follow-up 10-Year follow-up
Males XY 0.76 (0.60–0.97) 0.76 (0.61–0.96) 0.76 (0.61–0.94)
Females XX 0.41 (0.19–0.84) 0.52 (0.28–0.94) 0.67 (0.38–1.14)
Data in women have not yet been published in the final form.34
CT, computed tomography.
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(HR: 0.69, 95% CI: 0.52–0.93). This study presented par-
ticular limitations such as incomplete OS and PFS data
from all included RCT or differences in the number of
both men and women which may have finally
influenced definitive results.58
Finally, Dafni et al. included 9236 metastatic NSCLC
patients in their network meta-analysis, which compared
the efficacy of treatment protocols with at least one ICI,
with or without chemotherapy, as a first-line approach.
In this study, gender was evaluated for a possible differ-
ential effect on PFS/OS benefit: the same treatment com-
binations confirmed an advantage in both categories, but
it was interesting that pembrolizumab/chemotherapy
appeared more favourable for women than men.59
At the present time, there are not conclusive data to
recommend gender-specific treatment protocols. Sup-
plementary prospective studies should be designed to
specifically address sex differences. As stated by Colli
et al., well-conducted observational studies are needed
to balance the meticulous but limited data from RCT.
Combined results can represent one more step towards
gender-optimized immunotherapeutic strategies.56
In summary, many different factors including envi-
ronmental, hormonal and immunological influences
may contribute to the sex-specific differences between
lung cancer in men and women. This important area of
study is just beginning to be elucidated and more
research is needed to understand whether treatment
decisions to account for sex should be further personal-
ized in future.
THE DICHOTOMY OF LIVING LONG
TERM WITH A DEADLY CANCER
The rapidly changing treatment landscape of
lung cancer
Lung cancer is the most commonly diagnosed cancer
and the leading cause of cancer death worldwide
(18.4% of all cancer deaths).7 Historically, lung cancer
has been considered a recalcitrant cancer, with an
extremely low 5-year survival rate. In the United States,
the 5-year survival rate is currently 19.4% for all lung
cancers and only 5.2% when diagnosed as metastatic
disease.60 The low probability of survival has contrib-
uted to nihilism in the provider community and
impacted treatment referrals and pathways for people
with lung cancer.61
Fortunately, advances in treatment and detection
have changed the lung cancer landscape dramatically
in the past decade. In some countries, screening for
lung cancer is available that can shift diagnosis to ear-
lier stages and improve mortality rate for those at high
risk.34,62 In addition, NSCLC now has a host of treat-
ment options, which can be personalized, based on
biomarker testing results. Newer agents are resulting in
significant improvements in OS for distinct subgroups
of lung cancer patients. Immunotherapy has changed
the space and improved odds of long-term survival.
Notably, a recent study showed a nearly 30% 5-year
survival rate on first-line single agent immunotherapy
for patients with metastatic NSCLC that had high PD-
L1 biomarker levels.63 In addition, second- and third-
generation targeted therapies are improving survival
for biomarker-selected subsets of patients. For
advanced ALK-rearranged lung cancer, the 5-year OS
rate on frontline alectinib is 62.5%.64,65 For EGFR-
mutant lung cancers, osimertinib has now become the
primary first-line option in many countries, based on
the FLAURA trial where patients with advanced NSCLC
on osimertinib had a median 38.6-month OS compared
to 31.8 months for erlotinib or gefitinib.66
Collectively, these recent advances are resulting in
incremental survival improvements, with the latest
American Cancer Society statistics showing the largest
drop in lung cancer deaths in a single year.67 Specifi-
cally, as of 2017, the death rate has dropped from its
peak for lung cancer by 51% among males (since 1990)
and by 26% among females (since 2002). Improved sur-
vival from new, more effective therapies is resulting in
people living with lung cancer while actively on treat-
ment for extended periods of time. Consequently, more
and more people are living with lung cancer as a
chronic disease.
A brief history of chronic disease
Definitions of chronic disease vary. Broadly defined by
the United States Centers for Disease Control, a chronic
disease is a condition that lasts 1 or more years,
requires ongoing medical attention and/or limits activi-
ties of daily living.68
In the 1800s, the term ‘chronic’ referred only to the
extended period of disease and was not related to
severity. In the early part of the 20th century, there was
recognition that diseases could be disabling. As early as
1920, Casamajor recognized the changes and adjust-
ments necessary to navigate living with a chronic dis-
ease.69 Perrott and Holland70 were the first to explicitly
link chronic disease to disabling illness in 1937.
One hundred years after Casamajor, chronic disease
management has only become more complex. By defi-
nition, chronic illnesses ‘may be episodic—have acute
phases, be degenerative, or have remissions and create
uncertainty for those affected and others around
them’71 (page 632). This uncertainty can make those
diagnosed seem unpredictable and less desirable, both
occupationally and socially.72
Cancer as chronic disease
In 1953, Morton and Morton presented the concept of
chronic cancer through 17 cases,73 but no definition of
the term is offered. They found a ‘wide variation’ in the
response to treatment and observed ‘prognosis in
terms of survival time in an individual situation should
be given cautiously since any case may be well above
or below the general average’ (page 700). The ability to
predict the length of survival of a given individual with
cancer remains elusive today.
Importantly, in 1985, the National Coalition for Can-
cer Survivorship (NCCS) defined survivorship as begin-
ning at the time of diagnosis and continuing for the
balance of life. First put forth by an NCCS founder,
Mullan,74 three seasons of survivorship are outlined:
acute, extended and permanent. People living with
chronic cancer will recognize the acute season but
Respirology (2020) © 2020 Asian Pacific Society of Respirology
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never achieve the seasons of extended and permanent
survival.
The needs of people living with chronic cancer are
often not addressed in the literature or in practice. Lists
of chronic diseases do not always include cancer.75
Even within relevant Institute of Medicine reports
(2006’s From Cancer Patient to Cancer Survivor: Lost in
Transition; 2012’s Living Well with Chronic Disease;
and 2018’s Long-Term Survivorship after Cancer Treat-
ment), only brief reference is made to management of
chronic cancer, with more focus on managing the
long-term chronic, effects of cancer treatment.76–78
Berlinger and Gusmano79 points out that, overall,
cancer systems of care are not designed to meet the
needs of people with chronic cancer. One example of
the emotional toll this can take is the bell-ringing cere-
monies held in many cancer centres to celebrate the
end of treatment. It can be difficult, as a person living
with chronic cancer, to be routinely reminded of the
fact they will never reach this milestone. If a person
with chronic cancer reaches the ‘5-year survival’
benchmark, it is likely to have been accomplished
through a complicated trajectory of physical and psy-
chological ups and downs.
In 2012, Harley et al.80 offered a thoughtful explora-
tion of chronic cancer, recognizing limitations of the
current, broad concept of survivorship and lack of a
definition for chronic cancer and when it begins or
ends. Harley et al.’s definition—that the cancer is
incurable, advanced or metastatic but not at end-stage,
and for which there are active treatments available to
slow progression, prolong life or control symptoms—
mostly resonates for chronic cancer.
Given the current state of cancer care, Harley et al.’s
definition requires a few revisions (Table 2). Today,
clinical benefits from immunotherapies often remain
after treatment ends, so treatment no longer needs to
be active for the person to remain in the chronic phase.
Moreover, many people with cancer have survived for
years with a mutation-driven cancer through following
drug developments, changing from one targeted tyro-
sine kinase inhibitor to the next even when the drugs
are only available in clinical trials. Harley et al.’s defini-
tion makes no mention of clinical trials so the pro-
posed adaption (Table 2) includes as a treatment
option, a rational clinical trial with expectation of
potential clinical benefit for those who qualify.
Nearly 70 years after Morton and Morton’s study,
much of the chronic disease literature still does not
include chronic cancer, focusing on conditions such as
diabetes, asthma and hypertension. Chronic disease
management models and strategies that do not include
cancer do not always translate and may not address
the unique needs of this population.
Conceptualizing lung cancer as a chronic
disease
Despite advances in screening and treatment, lung can-
cer continues to be seen by some as an untreatable dis-
ease, a ‘death sentence’.81,82 Lung cancer is rarely, if
ever, included in chronic disease literature; however,
people have been living with chronic lung cancer for
some time.
In 1942, Goldman explored 11 lung cancer cases in
which the patient lived longer than 2 years.83 The sur-
vival length of these patients was remarkable at the
time but the article provides no insight into the experi-
ence of living with long-term lung cancer. Targeted
therapies, in use since the early 2000s, can extend sur-
vival for months or years. A 2011 study84 of 191 people
who had taken gefitinib for a minimum of 5.4 years
provides another historical example of people living
with chronic lung cancer.
However, there is little guidance for those living with
chronic lung cancer, who may have much in common
with those living with other chronic diseases but also
face specific challenges unique to a diagnosis of lung
cancer. Survival may have been achieved by moving
from one clinical trial to another, always testing the
newest treatment approaches. Treatment resistance is a
reality for those on targeted therapies so for them, ‘nor-
mal’ includes managing the anticipation of resistance
and always looking for the next potential treatment or
appropriate clinical trial. One lung cancer survivor,
diagnosed with ALK+ lung cancer, recognized the toll
this takes on the individual, calling her decade on clini-
cal trials, ‘a privilege and a burden’.84
Traditionally, lung cancer treatments result in high
side-effect burden, which leads to diminished quality
of life.73 Lung cancer’s link to smoking and the fact that
it is more commonly diagnosed in lower socio-
economic populations85 can change public perceptions
about the disease. People diagnosed with lung cancer
have greater unmet psychological and physical needs86
and experience higher rates of distress compared with
other types of cancer.87
Lung cancer stigma as a unique challenge
An especially difficult source of distress in lung cancer
is stigma, ‘a strong feeling in society that being in a
particular situation or having a particular illness is
something to be ashamed of’.88 Lung cancer stigma is
largely a consequence of the disease’s close association
with smoking, most notably outlined in the 1964 Sur-
geon General’s report, Smoking and Health.89 When
smoking is viewed as a lifestyle choice rather than a
powerful addiction, akin to heroin, cocaine and
alcohol,90 lung cancer diagnosed in a person with a
smoking history may be viewed as ‘self-inflicted’91 and
somehow deserved. The enduring results of lung can-
cer stigma at societal, interpersonal and personal levels
have resulted in great disparities in research funding
Table 2 Definition of chronic cancer (Adapted from
Harley et al.,80)
Defining characteristics of chronic cancer
Active, advanced or metastatic cancer
Is not considered curable
Treatment options including rational clinical trials are
available to slow disease, control symptoms and/or
prolong life OR the cancer is still responding to a prior
treatment option (such as with immunotherapy)
Patient is not at end-stage
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and detrimental impacts on the treatment of people
with lung cancer.
Research into the effects of lung cancer stigma has
been ongoing since 2004.91 Rates vary by study but
Shen et al.92 found 95% of people diagnosed with lung
cancer reported having experienced stigma in one form
or another. Current smokers, former smokers and
never-smokers all may face stigmatization.93 Individ-
uals with a history of smoking who are diagnosed with
lung cancer may experience shame and guilt.94 Loved
ones may say or do things that are stigmatizing95 and
differential treatment by members of the medical team
may be delivered or perceived.61,81 Those affected
may experience an increase in depression and isola-
tion74,81 and tragically, lung cancer stigma can result in
patients refusing, delaying or dropping out of
treatment.77–80
Societal stigma affects everyone diagnosed. Individ-
uals with lung cancer are subject to questions and
comments from strangers and acquaintances based on
public beliefs about the disease.96 There are even
adverse effects on drug development as lung cancer
research has been underfunded compared to other
cancers both at governmental levels and from non-
profit research funding entities.97 Until efforts to elimi-
nate stigma are unified,98 stigma will remain ‘a part of
the lung cancer experience’81 (page 16).
A diagnosis of any chronic disease also carries the
potential for stigma.99 Unemployment from a
chronic condition, particularly at a younger age, can
lead to the perception that the person is no longer a
valued member of society.71 If un/under employ-
ment is lost or limited and results in reliance on
public assistance programmes, an additional layer of
stigma may also be felt.100 Earnshaw et al. observed
‘People living with chronic illnesses may be per-
ceived as both unpredictable and having poor pros-
pects, therefore representing poor social exchange
partners...’72 (page 3).
Thus, conceptualizing lung cancer as a chronic dis-
ease may compound an existing burden from
‘intersectional stigma’, defined by Turan et al. as the
convergence of multiple stigmatized identities within a
person or group101 (page 1). This convergence has the
potential to magnify the negative effects of lung cancer
stigma on treatment-seeking behaviours, emotional
well-being and societal relationships and must be
addressed in any proposed management strategy for
this population.
Subpopulations within the lung cancer
community
As lung treatments change, so does the face of the dis-
ease. Much of the progress in treatment has been
spurred by the discovery of distinct driver mutations.
There are multiple actionable genetic changes for
which, in the United States, there are classes of
targeted therapies for seven genes (EGFR, ALK, ROS1,
BRAF, NTRK, RET and MET). Many clinical trials are
underway to target new alterations, including HER2
and KRAS G12C. There are also immunotherapy drug
approvals based on PD-L1 protein levels. Only now are
differences in the experiences and needs of these
unique subpopulations being recognized.
Lung cancers that are driven by single targetable
driver mutations are more prevalent in younger, never-
smoking patients.102 The Genomics of Young Lung Can-
cer study includes those diagnosed under the age of
40 and found that over 80% of participants have driver
mutations in their cancer.103 These subclasses of lung
cancers often respond to targeted therapies for months
or years. Each mutation is found in a small percentage
of all lung cancers but those with known biomarkers
are connecting online and organizing into global
patient groups. Members of these groups often identify
themselves as such: I am a ROS1der, an EGFR resister,
an ALK positive, etc.
Lung cancer screening by low-dose CT scan has
been shown to reduce mortality from the disease for
those in high-risk categories.34,62 A history of heavy
smoking and advancing age are the two most impor-
tant criteria that define high risk.104 Because those with
driver mutations are so often younger never-smokers,
they are ineligible for lung cancer screening. As a
result, like most cases worldwide, the lung cancer is
often diagnosed incidentally or when symptoms of
metastatic disease present.105 Even when symptomatic,
many never-smokers report being treated for other
conditions before lung cancer is considered a possibil-
ity, sometimes delaying diagnosis for months.106 The
uncertainty around what caused the lung cancer and
concerns around risk to other relatives that cannot be
answered at this time only increase the burden of the
disease for never smokers.106
Living with lung cancer as a chronic disease as a
young person can result in long-term unemployment
and financial consequences. Increased role strain exists
for those caring for young children and/or ageing par-
ents.107 Fertility preservation has not been a regular
concern for people diagnosed with lung cancer, but is
incredibly important for those diagnosed at a young
age. Long-term use of newer therapies is likely to lead
to effects not yet understood. As a result, traditional
care management approaches to lung cancer must be
reconsidered.
Moving forward in understanding lung
cancer as a chronic disease
The unique needs of those living with chronic lung
cancer have been largely unexplored until now. There
is a critical need to develop education and interven-
tions to help support people in this unknown space. To
do so, it is important to both learn lessons from
research into other chronic diseases as well as to learn
from the experts themselves—those who have been liv-
ing long term with the disease. Similar to other chronic
cancer patients, they are typically in continual treat-
ment, sometimes for years suspended between
unattainable cure and eventual death.
Adapting management strategies to lung
cancer
Managing a chronic disease is a lesson in balancing
illness-related burdens and demands while striving to
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maintain as much normality and quality of life as pos-
sible. The physical toll of continual treatment and side
effects can make it difficult to meet work and social
obligations. Regular appointments and attending to
other health-related matters can reduce time for other,
more pleasurable events, such as family functions and
vacations. It is necessary to plan ahead for potential
emergencies and other eventualities.108,109 Even when
able to maintain employment and health insurance,
co-pays, transportation and other treatment-related
costs can create serious financial concerns. The
unpredictability of costs may gravely affect the individ-
ual and family’s physical and emotional well-being.109
The additive problems can result in serious conse-
quences, including adherence issues; diminished
health and well-being; increased reliance on external
emotional and financial resources; employment uncer-
tainty; and overall strain on relationships and support
systems.108 While not the focus of this review, the sig-
nificant impact of chronic disease management on
caregivers and other loved ones cannot be overstated.
Current chronic disease management strategies exist,
but as Hammer et al.110 found, even those for chronic
cancer seem incomplete to meet the needs of those
receiving extended cancer treatment. None address the
unique and specific needs of the lung cancer popula-
tion. One promising chronic disease framework that
may be adapted to lung cancer is THRIVE,111 which
was developed and published in 2018 by an interna-
tional group of researchers after a thorough analysis
and thoughtful synthesis of qualitative and quantitative
chronic illness literature. The authors eloquently
describe the range of emotions people living with
chronic disease experience, which are completely rele-
vant to lung cancer, including grief, loss of control and
powerlessness. Disease stigma and potential isolation
are also recognized. Structured as determinants of cop-
ing with chronic illness, the key findings are organized
into the comprehensive, easy to understand THRIVE
acronym: Therapeutic interventions; Habit and behav-
ioural factors; Relational/social factors; Individual dif-
ferences; Values and beliefs; and Emotional factors.
THRIVE is not disease specific, is respectful of individ-
ual coping differences and infinitely personalizable.
It is easy to see coping with lung cancer as a chronic
disease in all six THRIVE domains but of particular
interest is that of Habit and behavioural factors. While
for some diagnosed with lung cancer, smoking cessa-
tion is an important component of treatment, nearly
80%112 of those diagnosed today are former or never
smokers. A near universal reaction to a cancer diagno-
sis is the feeling of loss of control. Unlike some chronic
diseases, behavioural changes like improving dietary
habits and increasing activity levels, while important,
will likely not directly influence the course of lung can-
cer as it might in diabetes and heart disease. THRIVE’s
H is not limited to lifestyle changes but includes esta-
blishing routines that are not disease-dependent;
developing hobbies; expanding social opportunities;
and developing goals that are flexible within the
unknowns of the disease trajectory.
An important unknown for people living with
chronic lung cancer are the cumulative physical and
emotional effects on health-related quality of life from
new lung cancer therapies taken over many years. It is
premature to speculate on these effects but efforts are
underway to study them. The Lung Cancer Registry,113
which includes participants from 51 countries, and
other studies are actively collecting quality of life data
and will help elucidate some of the unique and prob-
lematic effects on both people with chronic lung cancer
as well as long-term, out-of-treatment, survivors.114
Better understanding of these long-term effects will
inform key areas of THRIVE when used in lung cancer,
most notably emotional factors and Individual
differences.
Learning from first-hand experience
To begin to understand the key issues of people
experiencing extended lung cancer treatment, and to
inform future research, we surveyed and held in-
person focus groups with people with lung cancer
attending an advocacy summit. Those diagnosed at
least 2 years prior who had been in treatment continu-
ously or more often than not since diagnosis were
invited to participate. Twenty-two survey responses
were received, with 19 respondents participating in the
focus groups and one interviewed separately. All but
two participants were women. The age range at the
time of diagnosis was 26–66 years. The range of year of
diagnosis was from 2005 to 2017 and three quarters
had originally been diagnosed at stage IV. The informa-
tion gathered from these efforts provides important
background for future research in this area.
What’s in a name?. Collectively, responses from our
participants reflect the real struggle it can be to define
oneself when living in this space. Despite the widely
accepted use of the NCCS definition of ‘survivor’, the
term does not resonate with everyone diagnosed.115
For those living with chronic lung cancer, this may be
even more so. Prior to the focus groups, we surveyed
participants and asked how they refer to themselves
within the context of the diagnosis. Only 23% indicated
they use the word survivor alone. Another 27% quali-
fied it, saying they are a ‘lung cancer survivor’. In sub-
sequent group discussions, we learned that for some,
survivor implies treatment has ended or even that the
cancer has been cured. Other ways people identified
themselves included, ‘living while dying’ and ‘surviving
with lung cancer’.
What about the term ‘chronic disease’? Taylor and
Bury raised concerns that use of the term could ‘…
undermine political and professional awareness of the
complexity of illness experiences…’.116 To understand
the thoughts of our group participants, we presented
them with the previously outlined definition of chronic
disease68 and asked if it resonated. Interestingly, while
all participants fit the definition included in Table 2,
the majority did not identify with the concept of
chronic lung cancer. Some found it helpful but many
were unsure or quite negative in their reactions
(Table 3). When asked for alternate terminology, partic-
ipants who did not like the chronic concept suggested
‘living with lung cancer’, ‘incurable’, ‘terminal’, ‘some-
times treatable’, ‘life-threatening’ or ‘terminally ill for
an extended period of time’.
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The struggle to achieve balance. The oft-stated
goal after a cancer diagnosis of finding the ‘new nor-
mal’117 may never be achieved for those in this space,
for whom as Berlinger and Gusmano indicate ‘change
is constant’79 (page 122). Jeon et al.109 wrote eloquently
about the struggle to find balance while living with a
chronic disease. This theme of balance within such an
unpredictable disease was echoed by focus group par-
ticipants as they answered questions related to changes
they had made post-diagnosis and tips they could
provide to others.
The dichotomy of their answers highlights the strug-
gle to find balance (Fig. 2). The importance of being an
informed patient was stressed, asking questions and
even educating the oncologist, if necessary. But, it was
also advised to stay off the internet to avoid depressing
statistics and ‘worst case’ information. There are strug-
gles to prioritize tasks of everyday living. When the
focus is on the cancer and related appointments, it
can lead to neglect of other health issues. How can
going to the dentist be important when living with a
life-threatening illness?
It was also difficult to find stability in social relation-
ships. Some lost friends when they were diagnosed.
Others did not but said the relationships changed, even
deepened. Although facing a terminal diagnosis, some
participants did not want the perceptions of others to
change. ‘Just treat me like a regular person’. Others
remarked that because they so often do not look sick,
people can forget they have cancer and may not recog-
nize their struggles. The importance of finding ‘like’
others was also stressed. Especially important are the
online mutation-specific groups described above. How-
ever, deaths in these groups are inevitable and when
one experiences repeated losses that are so similar, the
grief can be immense. Survivor guilt, documented by
Perloff et al. in those living long term with lung
cancer,118 can result from these experiences.
Balance is even difficult in goal setting and life out-
look. Participants reported the need to cut out drama
and to know where to focus sometimes with limited
energies. Others said it is vital to ‘grab life by the horns’
and to ‘live like there is no tomorrow’. The responses
highlight the duality of living with lung cancer as a
chronic disease (Fig. 2). The strength, resilience and
perseverance shared in the experiences of focus groups
affirmed how much there is to learn and provide a
Table 3 Patient perceptions on the concept of lung
cancer as a chronic disease. Responses from focus
group participants who had been living with advanced
lung cancer for more than 2 years
Patient perceptions on lung cancer being described as a
chronic disease
Positively identifies with
the concept Not sure/does not identify
It gives hope. I tell people,
‘this is the face of lung
cancer’
It’s more than chronic
Better than ‘survivor’
because that implies cure.
I tell people, ‘I will always
have this disease’
It’s chronic but only until the
point the medication stops
working
Chronic allows people not to
think of the disease as a
death sentence
I’m not comfortable with
calling it chronic, but I
want it to be
I convinced myself of having
a ‘chronic’ disease
because the mind is
powerful. It’s not curable,
but treatable
I want to say ‘chronic’ but I
know it’s ‘terminal’





why I have to go to the
doctor so much
I do not expect to live to a
‘ripe old age’ like with a
chronic disease like
diabetes
People get it Chronic sounds like a
positive, ambitious goal
Constant magnification of and/or changes in:
• Confronting one’s mortality time and time again 
• Planning; inability or need to adjust  
• Financial and/or insurance status and barriers
• Role and relationship re-negotiation
• Coping with reactions of others 
• Anxiety levels
Improvements: 
• Intensification of joy
• Strengthened spirituality
• Deepening of relationships
• Clarification of priorities
• Ability to keep things in perspective  
• Improved self-care
“Living with cancer is like having 
a gun to your head most times.”
“Cancer has changed my life to 
the better, as crazy as it sounds.”
Figure 2 The duality of experiences of living with lung cancer as a chronic disease.
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call-to-action for us to learn more and to provide per-
sonalized information and support to these individuals.
It is perhaps fitting that we now examine lung cancer
as a chronic disease. In 1990, White119 made the case
that research into the causal effects of smoking on lung
cancer rates fundamentally changed how chronic dis-
ease epidemiology was conducted. The need for
improved epidemiological methods to determine if
smoking was truly casual led to methodology that has
advanced the study of chronic disease today. With
today’s rapid advances, the lung cancer community
faces new challenges: To implement systemic changes
and new approaches in order to care for the physical,
social and emotional well-being of those living with
lung cancer as a chronic disease.
CONCLUSIONS
Even as we know more about lung cancer than ever
before, there remains many unknown factors.
It seems women have different susceptibilities to
developing lung cancer, and respond to treatment dif-
ferently. These specific aspects, and others, underline
the need for further studies aimed at identifying
sex-specific factors. Previous efforts have been not suf-
ficient and more research is urgently needed, consider-
ing that lung cancer remains the least funded of the
major cancers affecting women.
As people live with lung cancer for longer and longer
periods of time, we look to both the cancer and the
chronic disease communities to mobilize so that we
can understand the specific patient-centric approaches
and public health changes that are needed properly
care for this fast growing population.
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